All In Biotech

Drug Trial Radar · NCT05662033

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.

A Blinded, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an Oral Suspension of AZD6793 Following Single and Multiple Ascending Doses in Healthy Subjects, an Open-label Study to Assess the Relative Bioavailability and Food Effect of a Tablet Formulation of AZD6793 in Healthy Subjects and a Blinded, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Tablet Formulation of AZD6793 in Patients With Chronic Obstructive Pulmonary Disease

Last checked: Nov 19, 2026Latest source record: Oct 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

93

Actual

Start

Dec 5, 2022

Primary completion

Oct 29, 2024

Study completion Oct 29, 2024

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the safety and tolerability of AZD6793 suspension following oral administration of Single Ascending Dose (SAD) \[Part 1\] and Multiple Ascending Dose (MAD) \[Part 2\] in healthy participants. Additionally, the study will include Part 3 (bioavailability and food effect cohort) to assess the relative oral bioavailability between test formulation and oral suspension (reference formulation) as well as the effect of a high fat high calorie (HFHC) meal on the PK of AZD6793 test formulation, in comparison to fasting conditions, after a single oral dose of AZD6793 in healthy participants. Part 4 of the study (Chronic Obstructive Pulmonary Disease \[COPD\] cohort) is intended to evaluate AZD6793 safety, tolerability, and PK profile for the first time in participants with moderate to severe COPD. Part 1 (SAD), Part 2 (MAD) and Part 3 (Bioavailability and food effect cohort) have been completed. Although it was planned that 5 cohorts would be included in Part 1, only 4 cohorts (32 participants) were included. Part 3 of the study was concluded with 13 healthy participants.

Conditions

  • Inflammatory Diseases

Interventions

  • AZD6793Drug

    AZD6793 will be administered orally

  • PlaceboDrug

    Placebo will be administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 (SAD): Number of participants with adverse eventsTime frame: From screening up to Follow up visit (Day 6±1)
  2. Part 2 (MAD): Number of participants with adverse eventsTime frame: From screening up to Follow up visit (Day 14±1)
  3. Part 1 (SAD): Number of participants with abnormal findings in vital signs (supine Blood Pressure (BP), pulse, respiratory rate, peripheral oxygen saturation (SpO2) and oral body temperature)Time frame: From screening, Treatment Day 1 to Day 4 up to Follow up visit (Day 6±1)
  4. Part 2 (MAD): Number of participants with abnormal findings in vital signs (supine Blood Pressure (BP), pulse, respiratory rate, peripheral oxygen saturation (SpO2) and oral body temperature)Time frame: From screening, Treatment Day -1 to Day 10 up to Follow up visit (Day 14±1)
  5. Part 1 (SAD): Number of participants with abnormal findings in 12 Lead electrocardiogram (ECG)Time frame: From screening, Treatment Day -1 to Day 4 up to Follow up visit (Day 6±1)
  6. Part 2 (MAD): Number of participants with abnormal findings in 12 Lead electrocardiogram (ECG)Time frame: From screening, Treatment Day -1 to Day 10 up to Follow up visit (Day 14±1)
  7. Part 1 (SAD): Number of participants with abnormal findings in 12 Lead Digital electrocardiogram (dECG)Time frame: Day 1 to Day 3
  8. Part 2 (MAD): Number of participants with abnormal findings in 12 Lead Digital electrocardiogram (dECG)Time frame: Day 1 to Day 3, Day 5, Day 8 to Day 10
  9. Part 1 (SAD): Number of participants with abnormal findings in TelemetryTime frame: Day -1 to Day 3
  10. Part 2 (MAD): Number of participants with abnormal findings in TelemetryTime frame: Day -1 to Day 2 and Day 8 to Day 10
  11. Part 1 (SAD): Number of participants with abnormal findings in Physical examinationsTime frame: From screening, Treatment Day -1 to 4 and follow up visit
  12. Part 2 (MAD): Number of participants with abnormal findings in Physical examinationsTime frame: From screening, Treatment Day -1 to 10 and follow up visit
  13. Part 1 (SAD): Number of participants with abnormal findings in Laboratory assessments (haematology, serum clinical chemistry, and urinalysis)Time frame: From screening, Treatment Day -1, Day 2, Day 4 and Follow up visit (Day 6±1)
  14. Part 2 (MAD): Number of participants with abnormal findings in Laboratory assessments (haematology, serum clinical chemistry, and urinalysis)Time frame: From screening, Treatment Day -1 to Day 10 up to Follow up visit (Day 14±1)
  15. Part 3 (Bioavailability): Maximum observed plasma (peak) drug concentration [Cmax]Time frame: Day 1 to Day 3
  16. Part 3 (Bioavailability): Area under plasma concentration-time curve from zero to infinity [AUCinf]Time frame: Day 1 to Day 3
  17. Part 3 (Food effect): Cmax of AZD6793Time frame: Day 1 to Day 3
  18. Part 3 (Food effect): AUCinf of AZD6793Time frame: Day 1 to Day 3
  19. Part 4 (COPD): Number of participants with adverse eventsTime frame: From screening up to Follow up visit (Day 34±2)
  20. Part 4 (COPD): Number of participants with abnormal findings in vital signs (supine Blood Pressure (BP), pulse, respiratory rate, peripheral oxygen saturation (SpO2) and oral body temperature)Time frame: From screening up to Follow up visit (Day 34±2)
  21. Part 4 (COPD): Number of participants with abnormal findings in 12 Lead electrocardiogram (ECG)Time frame: From screening up to Follow up visit (Day 34±2)
  22. Part 4 (COPD): Number of participants with abnormal findings in Physical examinationsTime frame: From screening, Treatment Day -1, 1, 14, 28 and follow up visit (34±2)
  23. Part 4 (COPD): Number of participants with abnormal findings in Laboratory assessments (haematology, clinical chemistry, coagulation tests, and urinalysis)Time frame: From screening up to Follow up visit (Day 34±2)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Harrow, United Kingdom

  • Research Site

    Wythenshawe, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.